Prevention of atrial fibrillation in patients with aortic valve stenosis with candesartan treatment after aortic valve replacement

International Journal of Cardiology

Volumn 165, Issue 2, 2013, Pages 242-246

  Dahl, Jordi S ^a   Videbæk, Lars ^a   Poulsen, Mikael K ^a   Pellikka, Patricia A ^b   Veien, Karsten ^a   Andersen, Lars Ib ^a   Haghfelt, Torben ^a   Møller, Jacob E ^c  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b MAYO CLINIC ROCHESTER   (United States)

^c University of Copenhagen   (Denmark)

Author keywords

Angiotensin II blockers; Aortic valve stenosis; Atrial fibrillation

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIURETIC AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE;

ADULT; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE INCREASE; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HOLTER MONITORING; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGED; AORTA VALVE PROSTHESIS; BLOOD SAMPLING; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; ELECTROCARDIOGRAPHY; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE HYPERTROPHY; HOSPITAL PATIENT; ISCHEMIC HEART DISEASE; PAROXYSMAL HEART ATRIUM FIBRILLATION; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PNEUMONIA; POSTOPERATIVE CARE; PREOPERATIVE PERIOD; PULSE PRESSURE; SINUS RHYTHM; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; THORAX PAIN;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; AORTIC VALVE STENOSIS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TETRAZOLES; TREATMENT OUTCOME;

EID: 84876693695     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.08.056     Document Type: Article

References (23)

1. V. Fuster, L.E. Ryden, and R.W. Asinger ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology Eur Heart J 22 20 Oct. 2001 1852 1923
2. G. Casaclang-Verzosa, B.J. Gersh, and T.S. Tsang Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation J Am Coll Cardiol 51 1 Jan. 1 2008 1 11
3. D. Li, K. Shinagawa, and L. Pang Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure Circulation 104 21 Nov. 20 2001 2608 2614
4. Y. Shi, D. Li, J.C. Tardif, and S. Nattel Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure Cardiovasc Res 54 2 May 2002 456 461
5. T.S. Tsang, M.E. Barnes, and W.P. Abhayaratna Effects of quinapril on left atrial structural remodeling and arterial stiffness Am J Cardiol 97 6 Mar. 15 2006 916 920
6. O.D. Pedersen, H. Bagger, L. Kober, and C. Torp-Pedersen Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction Circulation 100 4 Jul. 27 1999 376 380
7. K. Wachtell, M. Lehto, and E. Gerdts Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study J Am Coll Cardiol 45 5 Mar. 1 2005 712 719
8. J.S. Healey, A. Baranchuk, and E. Crystal Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis J Am Coll Cardiol 45 11 Jun. 7 2005 1832 1839
9. A.H. Madrid, M.G. Bueno, and J.M. Rebollo Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study Circulation 106 3 Jul. 16 2002 331 336
10. F. Belluzzi, L. Sernesi, P. Preti, F. Salinaro, M.L. Fonte, and S. Perlini Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients J Am Coll Cardiol 53 1 Jan. 6 2009 24 29
11. M. Disertori, R. Latini, and S. Barlera Valsartan for prevention of recurrent atrial fibrillation N Engl J Med 360 16 Apr. 16 2009 1606 1617
12. A. Goette, G. Breithardt, and T. Fetsch Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design Clin Drug Investig 27 10 2007 697 705
13. J.R. Ehrlich, S.H. Hohnloser, and S. Nattel Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence Eur Heart J 27 5 Mar. 2006 512 518
14. J.S. Dahl, L. Videbaek, and M.K. Poulsen Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis Am J Cardiol 106 5 Sep. 1 2010 713 719
15. V. Fuster, L.E. Ryden, and D.S. Cannom ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Europace 8 9 Sep. 2006 651 745
16. R.M. Lang, M. Bierig, and R.B. Devereux Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 12 Dec. 2005 1440 1463
17. R.B. Devereux, P.N. Casale, and P. Kligfield Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy Am J Cardiol 57 15 Jun. 1 1986 1388 1393
18. A. Ganau, R.B. Devereux, and M.J. Roman Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension J Am Coll Cardiol 19 7 Jun. 1992 1550 1558
19. T. Walther, A. Schubert, and V. Falk Left ventricular reverse remodeling after surgical therapy for aortic stenosis: correlation to Renin-Angiotensin system gene expression Circulation 106 12 Suppl. 1 Sep. 24 2002 I23 I26
20. B. Iung, G. Baron, and E.G. Butchart A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease Eur Heart J 24 13 Jul. 2003 1231 1243
21. E. Vermes, J.C. Tardif, and M.G. Bourassa Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials Circulation 107 23 Jun. 17 2003 2926 2931
22. P.L. L'Allier, A. Ducharme, P.F. Keller, H. Yu, M.C. Guertin, and J.C. Tardif Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation J Am Coll Cardiol 44 1 Jul. 7 2004 159 164
23. R. Caballero, R. Gomez, and I. Moreno Interaction of angiotensin II with the angiotensin type 2 receptor inhibits the cardiac transient outward potassium current Cardiovasc Res 62 1 Apr. 1 2004 86 95